Arcturus Therapeutics Holdings Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on June 5, 2026. The Company, Arcturus Therapeutics Holdings Inc., is incorporated in Delaware and trades on The NASDAQ Stock Market LLC under the symbol "ARCT".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 28,423,069 shares entitled to vote, 21,435,189 shares were present, constituting a quorum. The following proposals were approved:
- Proposal 1 (Election of Directors): All eight nominees were elected to the Board of Directors. Votes ranged from approximately 15.5 million to 15.6 million "For" votes per director, with withhold votes ranging from approximately 97,000 to 237,000.
- Proposal 2 (Say-on-Pay): The non-binding advisory resolution approving named executive officer compensation was approved with 15,254,240 votes "For", 327,647 "Against", and 176,375 "Abstain".
- Proposal 3 (Auditor Ratification): The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 21,378,017 votes "For", 46,823 "Against", and 10,349 "Abstain".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the full list of elected directors and their tenure terms in the definitive proxy statement filed on April 24, 2026.
- Confirm the specific compensation details for named executive officers referenced in the approved "say-on-pay" proposal.
- Review the upcoming fiscal year 2026 financial reports to assess the company's liquidity and operational status, as this 8-K contains no financial data.